UNI-MB - logo
UMNIK - logo
 
E-resources
Full text
Peer reviewed Open access
  • Time to blur the blast boun...
    DiNardo, Courtney D.; Garcia‐Manero, Guillermo; Kantarjian, Hagop M.

    Cancer, April 15, 2022, Volume: 128, Issue: 8
    Journal Article

    A fixed 20% blast percentage to discriminate myelodysplastic neoplasms from acute myeloid leukemia is arbitrary and overly simplistic. Key factors for identifying the optimal therapy for a patient with a myeloid malignancy should rely most on the patient's characteristics (particularly age and fitness/frailty) and disease cytogenetic and mutational profile, with less reliance on the bone marrow blast percentage.